Composition for improving cognitive function comprising natural extract complex and use thereof

Abstract

The present invention relates to: a composition for improving cognitive function, comprising a natural extract complex; and use thereof. According to an embodiment of the present invention, a composition for improving cognitive function or memory, comprising one or more selected from the group consisting of a Perilla frutescens var. acuta kudo extract, a Moringa oleifera extract, and a Phyllanthus emblica extract, exhibits few side effects due to being based on natural substances, is readily available, and provides an excellent cognitive function improvement effect while being cost-effective. Therefore, the composition can be effectively used for the prevention, amelioration or treatment of diseases associated with cognitive or memory impairment.

Description

Composition for improving cognitive function containing a complex of natural extracts and the use thereof

[0001] The present invention relates to a composition for improving cognitive function comprising a natural extract complex and the use thereof.

[0002] This invention is a study conducted with the support of the Gyeonggi Regional Cooperation Research Center (Project No. GRRCAjou2023-B01).

[0003] Cognitive impairment refers to an intermediate state where cognitive function has declined compared to normal elderly individuals, but independent daily living is still possible, making it impossible to diagnose as dementia; it signifies a condition with a very high risk of developing dementia. This decline in cognitive function is distinct from the natural phenomena that occur during the normal aging process and can be severe enough to interfere with daily life.

[0004] Mild cognitive impairment (MCI) is an early stage at risk of progressing to dementia, referring to a state where cognitive decline occurs but does not significantly affect daily life. Generally, MCI begins five years before the onset of dementia, and after six years, about 80% of these individuals reach the state of dementia.

[0005] While the causes of cognitive impairment are diverse, apoptosis, which leads to the damage and loss of nerve cells, is known to be the ultimate cause. Reactive oxygen species, which are highly oxidative oxygen molecules that damage cells, are identified as a major cause of neuronal cell death, the leading cause of degenerative neurological diseases. Oxidative stress caused by reactive oxygen species inflicts irreversible damage on brain cells and leads to cognitive impairments such as Parkinson's disease and Alzheimer's disease by causing changes in the structure and function of mitochondria.

[0006] As we enter a super-aged society, the incidence of neuropsychiatric disorders and Alzheimer's disease is increasing, and recently, 43.9% of the 2030 generation are suffering from 'Young-Alzheimer's,' which refers to severe forgetfulness in young adults.

[0007] To date, many patents related to compositions having efficacy in treating cognitive impairment, improving cognitive ability, or enhancing memory have been disclosed and registered in Korea. Publication No. 2014-0144785 relates to a composition for enhancing memory and learning ability containing yuzu extract as an active ingredient, and Registration No. 10-1823892 relates to an impatiens extract exhibiting effects of improving memory, improving cognitive ability, and preventing, delaying, or treating dementia.

[0008] In addition, representative drugs currently on the market for the treatment of cognitive impairment include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine). Donepezil increases the concentration of neurotransmitters by inhibiting the breakdown of acetylcholine in the brain, while memantine is effective in preventing cell damage by inhibiting excessive stimulation of nerve cells. However, side effects such as nausea, diarrhea, muscle spasms, and sleep disorders have been reported with donepezil, and side effects such as headache, drowsiness, dizziness, and vomiting may also occur with memantine.

[0009] Therefore, the development of therapeutic agents using biocompatible natural materials is advancing, and there is also a need to develop new materials with fewer side effects.

[0010] In order to solve the above-mentioned problems, the inventors completed the present invention by confirming the efficacy of a natural extract complex mixed with natural substances to improve cognitive ability and memory, based on the fact that natural substances such as Perilla frutescens var. acutakudo, Moringa oleifera, and amla (Phyllanthus emblica) are easily accessible, economical, and effective in improving cognitive ability.

[0011] Accordingly, the objective of the present invention is to provide a composition for improving cognitive function or memory comprising a natural extract complex composed of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

[0012] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of diseases related to cognitive impairment or memory impairment, comprising a complex of natural extracts selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

[0013] Another objective of the present invention is to provide a method for preventing or treating diseases related to cognitive impairment or memory impairment, comprising the step of administering the pharmaceutical composition to an individual.

[0014] Another objective of the present invention is to provide a food composition for improving cognitive function or memory comprising a natural extract complex composed of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

[0015] Another objective of the present invention is to provide a feed composition for improving cognitive function or memory comprising a natural extract complex composed of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

[0016] The terms used in this specification are for illustrative purposes only and should not be interpreted as being limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, terms such as "comprising" or "having" are intended to indicate the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should be understood as not precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.

[0017] Furthermore, unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the embodiments pertain. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.

[0018] In the case of duplicate content or terms in this invention, their description has been omitted to avoid excessive complexity in this specification.

[0019]

[0020] To achieve the above objective, according to one aspect of the present invention, a composition for improving cognitive function or memory is provided, comprising a natural extract complex consisting of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

[0021] The term "cognitive function" as used in the present invention refers to various intellectual abilities such as attention, perception, memory, language ability, and executive ability, and may be used interchangeably with "cognitive ability" or "cognitive intelligence."

[0022] The terms "memory" or "memory capacity" as used in this invention refer to the result of learning that persists over time, which involves acquiring new information obtained from the surrounding environment, learned experiences, or knowledge, encoding and storing them in specific parts of the brain, and the ability to recall them.

[0023] In one embodiment of the present invention, the perilla extract, moringa extract, and amla extract may be extracted using water, an organic solvent, or a mixture thereof as an extraction solvent, preferably water or a C1 to C4 lower alcohol, more preferably water, methanol, ethanol, or propanol as an extraction solvent, and most preferably hot water extraction at 70°C to 100°C using water as an extraction solvent.

[0024] In one embodiment of the present invention, the composition may be characterized by essentially including perilla extract and additionally including one or more selected from the group consisting of moringa extract and amla extract, and more specifically, may be characterized by including (a) perilla extract; and (b) one or more selected from the group consisting of moringa extract and amla extract, wherein (a) and (b) are mixed in a weight ratio of 1:1 to 1:4.

[0025]

[0026] According to another aspect of the present invention, a pharmaceutical composition for the prevention or treatment of diseases related to cognitive impairment or memory impairment is provided, comprising a natural extract complex composed of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

[0027] The term "cognitive impairment" as used in the present invention is a concept that may include a state resulting from a decline in cognitive function as described above, a disease resulting therefrom, and all diseases having such as a symptom, and preferably refers to an impairment caused by damage to brain nerve cells.

[0028] The term "memory disorder" as used in the present invention refers to a condition in which there is a problem with the ability to form, maintain, or recall memories, either temporarily or continuously, and includes hyperamnesia or memory decline. Memory disorder can occur even if any one of the three processes of memory recording, maintenance, and retrieval is impaired.

[0029] In the present invention, a disease related to cognitive impairment or memory impairment may specifically be a degenerative neurological disease, and more specifically, a disease related to cognitive impairment or memory impairment may refer to a degenerative brain disease selected from the group consisting of mild cognitive impairment (MCI), Parkinson's disease, Alzheimer's disease, amnesia, dementia, Pick's disease, and Huntington's disease.

[0030] The term "prevention" as used in the present invention refers to any act of suppressing or delaying the onset of cognitive impairment or memory impairment-related diseases by any one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract of the present invention.

[0031] The terms “improvement” or “treatment” used in the present invention refer to any act that improves or benefits parameters, such as the degree of symptoms, associated with cognitive impairment or memory impairment-related diseases due to one or more of the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract of the present invention.

[0032] The pharmaceutical composition of the present invention may be in various oral or parenteral formulations. When formulating the composition, it may be prepared using one or more buffers (e.g., saline solution or PBS), antioxidants, bacteriostatic agents, chelating agents (e.g., EDTA or glutathione), fillers, extenders, binders, adjuvants (e.g., aluminum hydroxide), suspending agents, thickening agents, wetting agents, disintegrants or surfactants, diluents or excipients.

[0033] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient with one or more compounds, for example, starch (including corn starch, wheat starch, rice starch, potato starch, etc.), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol, maltitol, cellulose, methyl cellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, or gelatin, etc. For example, tablets or sugar-coated tablets can be obtained by combining an active ingredient with a solid excipient, grinding the mixture, adding a suitable auxiliary agent, and processing it into a granular mixture.

[0034] In addition, lubricants such as magnesium stearate and talc are also used in addition to simple excipients. Liquid formulations for oral administration include suspensions, liquid formulations, emulsions, or syrups, and may contain various excipients, such as humectants, sweeteners, flavorings, or preservatives, in addition to commonly used simple diluents like water and liquid paraffin. Additionally, cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may be added as disintegrants, and may additionally include anticoagulants, flavorings, emulsifiers, solubilizers, dispersants, flavorings, antioxidants, packaging agents, pigments, and preservatives.

[0035] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, or suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions. Witepsol, macrogol, Tween 61, cocoa paste, laurin paste, glycerol, gelatin, etc. may be used as bases for suppositories.

[0036] The composition of the present invention may be administered orally or parenterally, and when administered parenterally, it may be formulated according to methods known in the art in the form of a topical application; an injectable; a transdermal application; or a nasal inhalant.

[0037] The above-mentioned injectable must be sterilized and protected from contamination by microorganisms such as bacteria and fungi. Suitable carriers for the injectable may include, but are not limited to, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), mixtures thereof, and / or vegetable oils, as solvents or dispersion media. More preferably, suitable carriers may include Hanks' solution, Ringer's solution, PBS (phosphate buffered saline) containing triethanolamine, sterile water for injection, isotonic solutions such as 10% ethanol, 40% propylene glycol, and 5% dextrose. To protect the injectable from microbial contamination, various antimicrobial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, and thimerosal may be additionally included. Additionally, the injectable may, in most cases, further include isotonic agents such as sugars or sodium chloride.

[0038] In the case of an inhalation dose, the compound used according to the present invention can be conveniently delivered in the form of an aerosol spray from a pressurized pack or atomizer using a suitable propellant, for example, dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve that delivers a metered amount. For example, gelatin capsules and cartridges used in an inhaler or blower can be formulated to contain the compound and a powder mixture of a suitable powder base, such as lactose or starch.

[0039] The composition of the present invention is administered in a pharmaceutically effective amount. A pharmaceutically effective amount refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. That is, the total effective amount of the composition of the present invention may be administered to the patient as a single dose, or administered via a fractionated treatment protocol involving long-term administration of multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by considering all the aforementioned factors, and this can be easily determined by a person skilled in the art.

[0040] The dosage of the pharmaceutical composition of the present invention varies depending on the patient's weight, age, gender, health status, diet, time of administration, method of administration, excretion rate, and severity of the disease. It may be increased or decreased depending on the route of administration, severity of obesity, gender, weight, age, etc.

[0041] The composition of the present invention can be used alone or in combination with methods using chemotherapy and biological response modifiers.

[0042]

[0043] Another aspect of the present invention provides a method for preventing or treating a disease related to cognitive impairment or memory impairment, comprising the step of administering the pharmaceutical composition to an individual.

[0044] The above "cognitive impairment," "memory impairment," "prevention," and "improvement" are as previously described.

[0045]

[0046] Another aspect of the present invention provides a food composition for improving cognitive function or memory comprising a natural extract complex composed of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

[0047] The term "food" used in the present invention includes meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, health functional foods, and health foods, and includes all foods in the conventional sense.

[0048] Since the food composition of the present invention can be consumed on a daily basis, it can be expected to have an effect of improving cognitive function or memory, and thus can be very usefully used for health promotion purposes.

[0049] The above-mentioned functional food is synonymous with food for special health use (FosHU) and refers to a food with high medical or therapeutic effects that is processed to efficiently exhibit bio-regulatory functions in addition to nutritional supply. Here, "functionality" means obtaining useful effects for health purposes, such as regulating nutrients or physiological actions regarding the structure and function of the human body. The food of the present invention can be manufactured by methods commonly used in the industry, and during such manufacturing, raw materials and ingredients commonly added in the industry may be added. Furthermore, the formulation of the food can be manufactured without restriction as long as it is a formulation recognized as a food. The food composition of the present invention can be manufactured in various forms of formulations. Unlike general pharmaceuticals, it uses food as a raw material, offering the advantage of not causing side effects that may occur with long-term use of pharmaceuticals. Additionally, due to its excellent portability, the food of the present invention can be consumed as an adjuvant to enhance cognitive function or memory improvement effects.

[0050] The aforementioned "health food" refers to food that has active effects in maintaining or promoting health compared to general food, and "health supplement food" refers to food intended for the purpose of health support. In some cases, the terms health functional food, health food, and health supplement food are used interchangeably.

[0051] Specifically, the above-mentioned health functional food is a food prepared by adding the compound of the present invention to food materials such as beverages, teas, spices, chewing gum, and confectionery, or by encapsulating, powdering, or suspension, and means that consuming it brings about specific health effects. Unlike general medicines, it has the advantage of not having side effects that may occur when taking medicine for a long period of time because it is made from food.

[0052] The above food composition may further include a physiologically acceptable carrier, the type of carrier is not particularly limited, and any carrier commonly used in the relevant technical field may be used.

[0053] In addition, the above food composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, visual appearance, etc. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, etc. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chromium (Cr); and amino acids such as lysine, tryptophan, cysteine, and valine.

[0054] In addition, the above food composition may include food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder and high-grade bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), etc.), coloring agents (tar dyes, etc.), colorants (sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG, monosodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), leavening agents (alum, potassium hydrogen tartrate, etc.), reinforcing agents, emulsifiers, thickeners (sizing agents), coating agents, gum bases, antifoaming agents, solvents, and improvers. The above additives may be selected according to the type of food and used in appropriate amounts.

[0055] As an example of the food composition of the present invention, it may be used as a health drink composition, in which case it may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages. The natural carbohydrates described above may be monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; and sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners may include natural sweeteners such as thaumatin and stevia extract; and synthetic sweeteners such as saccharin and aspartame. The proportion of the natural carbohydrates may generally be about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g, per 100 mL of the health drink composition of the present invention.

[0056] In addition to the above, the health drink composition may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, or carbonating agents. Furthermore, it may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, or vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health drink composition of the present invention.

[0057]

[0058] Another objective of the present invention is to provide a feed composition for improving cognitive function or memory comprising a natural extract complex composed of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

[0059] As used in the present invention, the term "feed" refers to any natural or artificial prescribed food, single meal, etc., or the components of said single meal, intended for or suitable for animals to eat, consume, and digest.

[0060] The types of the above feed are not particularly limited, and feeds commonly used in the relevant technical field may be used. Non-limiting examples of the above feed include plant-based feeds such as grains, root vegetables, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal, or grain by-products; and animal-based feeds such as proteins, inorganic substances, oils and fats, minerals, oils and fats, single-cell proteins, zooplankton, or food waste. These may be used individually or in a mixture of two or more types.

[0061] A composition for improving cognitive function or memory according to one embodiment of the present invention, comprising one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract, is based on natural materials, has few side effects, is accessible, and is economical, and has excellent cognitive function improvement effects, so it can be usefully utilized for the prevention, improvement, or treatment of diseases related to cognitive impairment or memory impairment.

[0062] Figure 1 shows the cognitive function improvement efficacy according to a Y-maze test at 50 mg / kg of a natural extract complex consisting of perilla, moringa, and amla in a mouse model of cognitive decline according to one embodiment of the present invention.

[0063] Figure 2 shows the cognitive function improvement efficacy according to a passive avoidance experiment of 50 mg / kg of a natural extract complex consisting of perilla, moringa, and amla in a mouse model of cognitive decline according to one embodiment of the present invention.

[0064] Figure 3 shows the neuroprotective efficacy of a natural extract complex composed of perilla, moringa, and amla according to one embodiment of the present invention.

[0065] The present invention will be explained in more detail below through examples. The following examples are intended solely to explain the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention.

[0066]

[0067] Example 1. Preparation of Perilla extract, Moringa extract, and Amla extract

[0068] Hot water extracts of Perilla frutescensvar. acutakudo, Moringa oleifera, or Amla were prepared by extracting Perilla frutescensvar. acutakudo, Moringa oleifera, or Amla at 80 ℃ and then sterilizing at 121 ℃ for 20 minutes (ChaW, MoW, AmW).

[0069]

[0070] Example 2. Construction of a Sleep Deprivation (SD) Stress Model

[0071] To induce a decline in cognitive ability in mice, a sleep deprivation stress model was constructed. First, eight platforms were installed in the rat cages and four in the mouse cages, and water was filled up to 1 cm below the platforms. Subsequently, utilizing the principle that placing experimental animals on the platforms prevents them from reaching a sleep state because their bodies come into contact with the water when they fall asleep or doze off, rats or mice were placed in each cage and sleep was continuously deprived for approximately 72 hours while changing the water every 24 hours.

[0072]

[0073] Example 3. Y-maze test

[0074] To determine whether the natural extract complex was effective on mice with induced cognitive decline, a Y-maze test was conducted. The Y-maze test is an experiment designed to evaluate the voluntary alternation behavior ability of mice and was performed on an acrylic plate measuring 3 cm in width, 36 cm in length, and 15 cm in height. After designating zones A, B, and C, mice were carefully placed in one zone, and their movement paths within the zones they entered were observed and recorded for 8 minutes. Subsequently, spontaneous alteration was evaluated by measuring the number of times and the order in which the mice entered each maze. One point was awarded for entering three different zones sequentially, while no points were awarded for non-consecutive entry. Alternation behavior (%) was calculated using the following formula.

[0075] [Calculation Formula]

[0076]

[0077]

[0078] Example 4. Passive avoidance task

[0079] To determine whether the natural extract complex was effective on mice with induced cognitive decline, a passive avoidance experiment was conducted. The passive avoidance experiment, designed to evaluate the short-term memory of mice regarding unpleasant stimuli, was performed in a shuttle box consisting of two chambers—a light room and a dark room—made of black polyvinyl plastic with a 20 × 20 × 20 cm floor covered with a 2 mm grid. The chambers were separated by a guillotine door. The light room was equipped with a 50W light bulb, while the dark room was connected to an electrical stimulator to allow electricity to flow along the grid. Mice were placed in the illuminated section and given a 20-second exploration period; afterward, the guillotine door was opened, allowing them to enter the dark section. Once it was confirmed that all four paws had entered, the door was closed, and a 0.5 mA electrical stimulus was applied for 3 seconds to initiate fear learning (acquisition trial).

[0080] After 24 hours, the mice were placed back in the brightly lit compartment, and after a 20-second search period, the guillotine door was opened to allow entry into the dark compartment. The time it took for all four paws to enter the dark compartment (latency time) was measured (retention trial). Mice that did not move into the dark compartment until 40 seconds had elapsed after the opening of the guillotine-shaped door were excluded from the experiment.

[0081]

[0082] Example 5. Measurement of cell viability

[0083] To confirm the neuroprotective efficacy of the natural extract complex according to the present invention, cell viability was evaluated using an MTT assay.

[0084] First, place 5 × 10 HT22 cells per well in a 96-well plate.3 After seeding the cells, they were cultured for 24 hours. Subsequently, the cells were divided and pretreated for 2 hours with a single natural extract and a natural extract complex dissolved in DPBS (Dulbecco's Phosphate-Buffered Saline). After pretreatment, glutamate (final concentration 10 mM) was added to each well, and the cells were cultured for an additional 24 hours. Afterward, MTT reagent (final concentration 5 mg / mL, dissolved in pH 7.4 DPBS) was added to each well, and the reaction was carried out for a certain period of time. After treatment with MTT reagent, 100 μL of DMSO was added to each well to dissolve the formed formazan crystals, and the reaction was allowed to proceed at room temperature for a certain period of time, after which the absorbance (OD) value was measured at 540 nm.

[0085]

[0086] The effects of the present invention will be explained below through experimental examples. However, the effects of the present invention are not limited to the following experimental examples.

[0087]

[0088] Experimental Example 1. Confirmation of cognitive improvement efficacy of a natural extract complex composed of Perilla frutescens, Moringa, and Amla in a mouse model of cognitive decline.

[0089] To confirm the cognitive function-improving efficacy of a natural extract complex composed of Perilla frutescens, Moringa, and Amla according to the present invention, Perilla frutescens water extract, Moringa water extract, and Amla water extract were prepared in the same manner as in Example 1. Then, 0.9% physiological saline (VEH), Perilla frutescens water extract 10 mg / kg + Moringa water extract 40 mg / kg (Perilla W + Moringa W) and Perilla frutescens water extract 10 mg / kg + Amla water extract 40 mg / kg (Perilla W + Amla W) were administered to the sleep-deprived mouse model of Example 2 at set times for 3 days to establish a control group and an experimental group. Subsequently, the cognitive function-improving efficacy of the natural extract complex was confirmed through cognitive ability evaluation of the control group and the experimental group, and the results are shown in Figures 1 and 2.

[0090] Looking at Figure 1, in the case of the 0.9% physiological saline administration group (VEH), the ability to change was reduced when the Y-maze test was performed. However, when 10 mg / kg of Perilla leaf water extract + 40 mg / kg of Moringa water extract (ChaWMoW) and 10 mg / kg of Perilla leaf water extract + 40 mg / kg of Amla water extract (ChaWAmW) were administered, the ability to change increased compared to VEH, and it was confirmed that the ability to change was higher than that of the control group, confirming that cognitive function was fully recovered.

[0091] Looking at Figure 2, in the case of the 0.9% physiological saline administration group (VEH), latency increased slightly in the retention trial when a passive avoidance test was performed. However, when 10 mg / kg of Perilla leaf water extract + 40 mg / kg of Moringa water extract (ChaWMoW) and 10 mg / kg of Perilla leaf water extract + 40 mg / kg of Amla water extract (ChaWAmW) were administered, latency increased significantly in the retention trial compared to the VEH and control groups, confirming that the efficacy in improving cognitive function was excellent.

[0092]

[0093] Experimental Example 2. Confirmation of neuroprotective efficacy of a natural extract complex composed of Perilla frutescens, Moringa, and Amla

[0094] To confirm the neuroprotective efficacy of the natural extract complex composed of Perilla frutescens, Moringa, and Amla according to the present invention, cell viability was evaluated using an MTT assay in the same manner as in Example 5, and the results are shown in Figure 3.

[0095] Looking at Figure 3, in the case of the 0.9% physiological saline administration group (VEH), cell viability decreased by nearly half compared to the untreated control group. However, in the group administered perilla water extract (ChaW), the group administered moringa water extract (MoW), and the group administered amla water extract (AmW), cell viability increased compared to VEH. Furthermore, in the group administered perilla water extract + moringa water extract (ChaWMoW) and the group administered perilla water extract + amla water extract (ChaWAmW), cell viability recovered to a level close to that of the control group compared to the single material administration group, confirming that there is a synergistic effect between the complexes.

[0096]

[0097] As such, the present invention has been described with reference to one embodiment, but this is merely illustrative, and those skilled in the art will understand that various modifications and equivalent alternative embodiments are possible therefrom. Accordingly, the true technical scope of protection of the present invention should be determined by the technical spirit of the appended claims.

[0098] A composition for improving cognitive function or memory according to one embodiment of the present invention, comprising one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract, is based on natural materials, has few side effects, is accessible, and is economical, and has excellent cognitive function improvement effects, so it can be usefully utilized for the prevention, improvement, or treatment of diseases related to cognitive impairment or memory impairment, and thus has industrial applicability.

Claims

1. A composition for improving cognitive function or memory comprising a complex of natural extracts consisting of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

2. In Paragraph 1, A composition for improving cognitive function or memory, wherein the above extraction is performed using water, an organic solvent, or a mixture thereof as an extraction solvent.

3. In Paragraph 1, A composition for improving cognitive function or memory, characterized in that the above natural extract complex essentially includes perilla extract and additionally includes one or more selected from the group consisting of moringa extract and amla extract.

4. In Paragraph 3, A composition for improving cognitive function or memory, characterized in that the above natural extract complex comprises (a) perilla extract; and (b) one or more selected from the group consisting of Moringa extract and Amla extract, wherein (a) and (b) are mixed in a weight ratio of 1:1 to 1:

4.

5. A pharmaceutical composition for the prevention or treatment of diseases related to cognitive impairment or memory impairment, comprising a complex of natural extracts composed of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

6. In Paragraph 5, A pharmaceutical composition in which the above-mentioned cognitive impairment or memory impairment-related disease is a degenerative brain and nervous system disease.

7. In Paragraph 5, A pharmaceutical composition wherein the above-mentioned cognitive impairment or memory impairment-related disease is mild cognitive impairment (MCI), Alzheimer's disease, or Parkinson's disease.

8. A method for preventing or treating a disease related to cognitive impairment or memory impairment, comprising the step of administering the pharmaceutical composition of claim 5 to an individual.

9. In Paragraph 8, A method for the prevention or treatment of a cognitive impairment or memory impairment-related disease, wherein the above-mentioned cognitive impairment or memory impairment-related disease is a degenerative brain and nervous system disease.

10. In Paragraph 8, A method for preventing or treating a cognitive impairment or memory impairment-related disease, wherein the above-mentioned cognitive impairment or memory impairment-related disease is mild cognitive impairment (MCI), Alzheimer's disease, or Parkinson's disease.

11. A food composition for improving cognitive function or memory comprising a complex of natural extracts composed of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

12. A feed composition for improving cognitive function or memory comprising a natural extract complex consisting of one or more selected from the group consisting of Perilla frutescens var. acutakudo extract, Moringa oleifera extract, and Amla Phyllanthus emblica extract.

Images